ravidasvir
Small moleculeexperimental
Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4. — Wikipedia
Clinical trial activity
14 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01448200)
Timeline
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
- Nonstructural protein 5AINHIBITOR
Nonstructural protein 5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3cc(-c4ccc5[nH]c([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc3c2)c[nH]1)C(C)C- Mol. weight
- 762.91 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3121849 ↗
- WikipediaRavidasvir ↗
- ChEMBLCHEMBL3545312 ↗
Also known as
- bi-238630
- bi-238630
- bi-238630-cl2
- bi-238630-cl2
- c5
- c5
- ppi-668
- ppi-668
- ppi-668
- ppi-668 free base
- ppi-668 free base
- ravidasvir
- ravidasvir
- ravidasvir
- ravidasvir hydrochloride
- ravidasvir hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04885855 | Phase 2/Phase 3 (Phase 3) | Mar 23, 2021 | Hospital Sultanah Bahiyah |
| NCT04358523 | Phase 1 | Mar 20, 2020 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03602300 | Phase 1 | Jun 5, 2018 | Drugs for Neglected Diseases Initiative, KPJ Ampang Puteri Specialist Hospital |
| NCT03430830 | Phase 1 | Jan 15, 2018 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03288636 | Phase 1 | Aug 8, 2017 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03362814 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2017 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03020134 | Phase 1 | Jul 1, 2016 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03020095 | Phase 2 | Aug 1, 2015 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT02371408 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2015 | Cairo University, Pharco Pharmaceuticals |
| NCT02258321 | Phase 1 | Oct 1, 2014 | Presidio Pharmaceuticals |
| NCT01979484 | Phase 1 | Oct 1, 2013 | Presidio Pharmaceuticals |
| NCT01859962 | Phase 2 | May 1, 2013 | Boehringer Ingelheim, Presidio Pharmaceuticals |
| NCT01786382 | Phase 1 | Feb 1, 2013 | Presidio Pharmaceuticals, Spaulding Clinical Research Inc. |
| NCT01448200 | Phase 1 | Oct 1, 2011 | Presidio Pharmaceuticals |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascletis Pharmaceuticals Co., Ltd. | For profit | 6 | 6 | 3 | 2015 |
| Presidio Pharmaceuticals | For profit | 5 | 5 | 2 | 2011 |
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 2013 |
| Cairo University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Drugs for Neglected Diseases Initiative | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Hospital Sultanah Bahiyah | Academic/Hospital | 1 | 1 | 1 | 2021 |
| KPJ Ampang Puteri Specialist Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Pharco Pharmaceuticals | For profit | 1 | 1 | 1 | 2015 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2013 |
9 organizations
Page 1 / 1